News | Quality Assurance (QA) | September 16, 2019

Company will highlight new tools for workflow automation and emergent techniques

Sun Nuclear Presents Portfolio of Independent Radiotherapy QA Solutions at ASTRO 2019

The PlanCheck module now part of SunCheck, automates plan quality checks, validates treatment plans against requirements, and automatically assesses plan performance versus intent.


September 16, 2019 — At the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, running Sept. 15-18 in Chicago, Sun Nuclear Corp. will present novel advancements in radiation oncology quality management.

For the SunCheck Quality Management Platform, Sun Nuclear introduces PlanCheck. This new module within the SunCheck Patient workflow automates plan quality checks, validates treatment plans against requirements, and automatically assesses plan performance versus intent. At ASTRO 2019, Sun Nuclear will also highlight SunCheck's expanded direct device integration, plus support for Varian Halcyon System secondary dose calculations, pre-treatment quality assurance (QA) and in-vivo monitoring.

Sun Nuclear will also introduce new Precision Laser Systems for positron emission tomography/computed tomography (PET/CT) simulation, magnetic resonance (MR) simulation, MR-guided radiotherapy (RT) and linear accelerator (linac)-based RT. Redesigned to better fit clinical workflows, CT SIM+ and MICRO+ laser systems offer high precision and accuracy at the patient, with what the company calls unmatched reliability, laser line definition and laser line length. Compatible with all major third-party systems, CT SIM+ software provides automation for enhanced patient focus.  

Beyond workflow automation support, Sun Nuclear enables adoption of emergent treatment techniques, including stereotactic radiosurgery (SRS) and MR-guided radiation therapy (MRgRT).

Enhancing the Sun Nuclear SRS QA portfolio is the introduction of the MultiMet-WL Cube. The device quantifies the margin of error for off-axis SRS targets, measuring error margins for single-isocenter multiple metastases treatments. Further supporting SRS programs are advancements with SRS MapCheck, including support for the Accuray CyberKnife System and vertex fields, including HyperArc. 

Sun Nuclear addresses the challenges of MRgRT with a suite of solutions, including ArcCheck-MR and IC Profiler-MR. Available soon and on display at ASTRO, Daily QA-MR will become the first commercially available daily QA system for MR-linacs.

For more information: www.sunnuclear.com

Related Content

News | Radiation Therapy

August 19, 2022 — Recently published research out of VCU Massey Cancer Center demonstrated that cancer patients who live ...

Time August 19, 2022
arrow
News | Breast Imaging

August 19, 2022 — The Christ Hospital Health Network, known for providing the best, most compassionate care for its ...

Time August 19, 2022
arrow
News | Proton Therapy

August 19, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time August 19, 2022
arrow
News | Prostate Cancer

August 16, 2022 — A new study published by University of Kentucky Markey Cancer Center researchers suggests that the ...

Time August 16, 2022
arrow
News | Breast Imaging

August 15, 2022 — Brainlab announced the first group of breast cancer patients treated in United States with the ...

Time August 15, 2022
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Did you know that Imaging Technology News (ITN) maintains more than 40 comparison charts of product specifications from ...

Time August 12, 2022
arrow
News | ASTRO

August 12, 2022 — The American Society for Radiation Oncology (ASTRO) today expressed its support for President Joseph R ...

Time August 12, 2022
arrow
News | Lung Imaging

August 10, 2022 — Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 ...

Time August 10, 2022
arrow
News | Prostate Cancer

August 9, 2022 — Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD ...

Time August 09, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
Subscribe Now